<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04875351</url>
  </required_header>
  <id_info>
    <org_study_id>BTX-BCI-016-PRT</org_study_id>
    <nct_id>NCT04875351</nct_id>
  </id_info>
  <brief_title>Breast Cancer Index (BCI) Registry</brief_title>
  <official_title>Breast Cancer Index (BCI) Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotheranostics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotheranostics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Breast Cancer Index (BCI) Registry study is to conduct a large scale,&#xD;
      population-based prospective registry to evaluate long-term clinical outcome, clinical&#xD;
      impact, medication adherence and quality of life in hormone receptor positive (HR+)&#xD;
      early-stage breast cancer patients receiving BCI testing as part of routine clinical care to&#xD;
      inform extended endocrine therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The BCI Registry is designed as a large-scale data registry and biospecimen repository to&#xD;
      evaluate the clinical outcome of hormone receptor positive (HR+) early-stage breast cancer&#xD;
      patients completing primary adjuvant endocrine therapy and are considering extended endocrine&#xD;
      treatment. The impact of BCI test results on extended endocrine therapy decision-making and&#xD;
      clinical use patterns will be characterized. Extended endocrine therapy-specific medication&#xD;
      adherence will be assessed annually. Primary tumor tissue will be collected for scientific&#xD;
      research purposes including molecular profiling and for correlative studies. The sample size&#xD;
      will consist of approximately 3,000 subjects across 30-50 sites in the United States.&#xD;
&#xD;
      The BCI registry will recruit patients with HR+ stage I to III breast cancer following an&#xD;
      initial 4-7 years of adjuvant endocrine therapy that will have BCI testing performed as part&#xD;
      of routine clinical care and meet the inclusion/exclusion criteria. After signing the&#xD;
      informed consent form (ICF) during screening, physicians and patients will complete the&#xD;
      pre-test Decision Impact Questionnaire. Upon ordering BCI by the treating physician, primary&#xD;
      tumor tissue obtained from the patient during previous breast-conserving surgery or&#xD;
      mastectomy will be requested by Biotheranostics to perform BCI testing at Biotheranostics'&#xD;
      CLIA certified and CAP accredited clinical laboratory in San Diego, CA. Following BCI&#xD;
      testing, the physician will share and discuss the BCI results with their patients and&#xD;
      recommend to either stop or extend endocrine therapy for an additional 5 years. The impact of&#xD;
      the BCI test results on extended endocrine therapy decision-making will be assessed using the&#xD;
      post-test Decision Impact Questionnaire, which will be completed by both physicians and&#xD;
      patients. In addition, medication adherence will be evaluated in patients that are&#xD;
      recommended for or elect to continue treatment to complete 10 years of adjuvant endocrine&#xD;
      therapy.&#xD;
&#xD;
      BCI reports both a prognostic and predictive result and has been shown to significantly&#xD;
      stratify patients based on the risk of late distant recurrence as well as to predict the&#xD;
      likelihood of benefit from endocrine therapy in multiple prospective-retrospective studies&#xD;
      within randomized controlled trial cohorts. The BCI registry study will determine the&#xD;
      long-term outcome and BCI test performance to add prospective validation for the prognostic&#xD;
      and predictive capabilities of BCI. In this context, the impact of BCI test results on&#xD;
      treatment decision-making and subsequently prescribed treatments will be characterized.&#xD;
&#xD;
      Analysis of BCI test performance with long-term outcome will be performed by Kaplan-Meier&#xD;
      analysis with log-rank test to assess the statistical significance of the risk stratification&#xD;
      by BCI risk groups. Cox proportional hazards regression will be used to derive the hazard&#xD;
      ratios (HR) and the associated 95% confidence intervals for the comparison of BCI risk&#xD;
      groups. Univariate and multivariate analysis adjusting for clinical factors such as age,&#xD;
      tumor size, grade, and treatment background (adjuvant endocrine therapy and chemotherapy)&#xD;
      will be conducted. Descriptive statistics will be used to evaluate the decision-impact and&#xD;
      medication adherence scores of patients enrolled in the study.&#xD;
&#xD;
      Each participating site will maintain appropriate medical and research records for this&#xD;
      trial, in compliance with Section 4.9 of the ICH E6 GCP, and regulatory and institutional&#xD;
      requirements for the protection of confidentiality of subjects. As part of participating in a&#xD;
      Biotheranostics-sponsored study, each site will permit authorized representatives of the&#xD;
      sponsor and regulatory agencies to examine clinical records for the purposes of quality&#xD;
      assurance reviews, audits and evaluation of the study progress. The clinical trial manager&#xD;
      will be in regular contact with the site research leader to check on progress and address any&#xD;
      queries that they may have. Sites may be suspended from participating in the registry in the&#xD;
      event of serious and persistent non-compliance with the protocol and/or Good Clinical&#xD;
      Practice. Any major problems identified will be reported to the Trial Management Team and if&#xD;
      necessary, the relevant regulatory bodies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2021</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">December 2028</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>To determine BCI test performance by evaluating the long-term outcome of BCI risk groups over the follow-up period.</measure>
    <time_frame>5 Years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine medication adherence in patients undergoing extended endocrine therapy.</measure>
    <time_frame>5 Years</time_frame>
    <description>Patients will be asked to complete a Medication Adherence Questionnaire during routine follow-up visits. Medication adherence scores over time will be evaluated in patients that are recommended for or elect to continue treatment to complete 10 years of adjuvant endocrine therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To prospectively assess the impact of BCI on extended endocrine therapy decision-making.</measure>
    <time_frame>5 Years</time_frame>
    <description>The impact of the BCI test results on extended endocrine therapy decision making will be measured using pre- and post-test Decision Impact Questionnaires, which will be completed by both physicians and patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To correlate BCI results with molecular tumor profiles in early stage breast cancer.</measure>
    <time_frame>5 Years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Breast Cancer Index (BCI) Risk of Recurrence &amp; Extended Endocrine Benefit Testing</arm_group_label>
    <description>Female patients diagnosed with hormone receptor-positive (HR+), lymph node-negative (LN-) or lymph node-positive (LN+, with 1-3 positive nodes) early-stage invasive breast cancer, who are distant recurrence-free.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Breast Cancer Index (BCI) Risk of Recurrence &amp; Extended Endocrine Benefit Test</intervention_name>
    <description>The BCI test provides a quantitative estimate of the risk for both late (post-5 years from diagnosis) distant recurrence and of the cumulative distant recurrence risk over 10 years (0-10y) in patients treated with adjuvant endocrine therapy (LN- patients) or adjuvant chemoendocrine therapy (LN+ patients), and prediction of the likelihood of benefit from extended (&gt;5 year) endocrine therapy.</description>
    <arm_group_label>Breast Cancer Index (BCI) Risk of Recurrence &amp; Extended Endocrine Benefit Testing</arm_group_label>
    <other_name>Breast Cancer Index (BCI) Test</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumor Tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study will include patients with stage I-III HR+ breast cancer that have signed an&#xD;
        informed consent. Patients seen within a physician practice participating in the registry&#xD;
        are potential candidates after meeting eligibility criteria requirements.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Early stage (I, II or III) female breast cancer patients, who have completed 4-7 years&#xD;
             of primary adjuvant endocrine therapy&#xD;
&#xD;
          -  Patient was diagnosed with invasive breast carcinoma (ductal, lobular, or mixed&#xD;
             ductal/lobular).&#xD;
&#xD;
          -  The primary tumor was hormone receptor positive (HR+), i.e. estrogen receptor-positive&#xD;
             and/or progesterone receptor-positive.&#xD;
&#xD;
          -  The primary tumor was HER2 negative or positive and node-negative or node-positive&#xD;
             with 1-3 positive lymph nodes.&#xD;
&#xD;
          -  Subject has pre-treatment breast tumor tissue [formalin fixed and paraffin embedded&#xD;
             (FFPE)] from a previous breast-conserving surgery, mastectomy or core needle biopsy&#xD;
             available for testing by the Sponsor.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has distant metastatic disease (M1).&#xD;
&#xD;
          -  Patient was diagnosed with metaplastic breast cancer, carcinosarcoma, sarcoma,&#xD;
             neuroendocrine carcinoma, adenoid cystic carcinoma, or phyllodes tumor.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joyce A O'Shaughnessy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>US Oncology Network</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Catherine A Schnabel, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Biotheranostics, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kai Treuner, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Biotheranostics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brandon N O'Neal, MS</last_name>
    <phone>858-314-9304</phone>
    <email>brandon.oneal@biotheranostics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southern Cancer Center, P.C. - Daphne</name>
      <address>
        <city>Daphne</city>
        <state>Alabama</state>
        <zip>36526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karla Childers</last_name>
      <phone>251-433-9899</phone>
      <email>karla.childers@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Michael Meshad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Cancer Center, PC - Mobile Infirmary</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karla Childers</last_name>
      <phone>251-433-9899</phone>
      <email>karla.childers@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Michael Meshad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Cancer Center, PC - Providence Hospital</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karla Childers</last_name>
      <phone>251-433-9899</phone>
      <email>karla.childers@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Michael Meshad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Cancer Center, PC - Springhill Medical Center</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karla Childers</last_name>
      <phone>251-433-9899</phone>
      <email>karla.childers@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Michael Meshad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - Glendale - Saguaro Cancer Center</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Thomas</last_name>
      <phone>623-487-4822</phone>
      <email>theresa.thomas@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Govardhanan Nagaiah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - Goodyear</name>
      <address>
        <city>Goodyear</city>
        <state>Arizona</state>
        <zip>85395</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Thomas</last_name>
      <phone>623-269-4222</phone>
      <email>theresa.thomas@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Govardhanan Nagaiah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - Phoenix - Biltmore Cancer Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Thomas</last_name>
      <phone>602-277-4868</phone>
      <email>theresa.thomas@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Govardhanan Nagaiah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - Phoenix - Deer Valley</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Thomas</last_name>
      <phone>623-879-4419</phone>
      <email>theresa.thomas@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Govardhanan Nagaiah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Thomas</last_name>
      <phone>480-860-2540</phone>
      <email>theresa.thomas@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Govardhanan Nagaiah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - East Valley Cancer Center</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85284</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Thomas</last_name>
      <phone>480-256-1664</phone>
      <email>theresa.thomas@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Govardhanan Nagaiah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sansum Clinic - Ridley-Tree Cancer Center</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Heitkamp</last_name>
      <phone>805-879-0670</phone>
      <email>hheitkam@ridleytreecc.org</email>
    </contact>
    <investigator>
      <last_name>Gregg C Newman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sansum Clinic - Ridley-Tree Cancer Center (Solvang)</name>
      <address>
        <city>Solvang</city>
        <state>California</state>
        <zip>93463</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Heitkamp</last_name>
      <phone>805-686-5370</phone>
      <email>hheitkam@ridleytreecc.org</email>
    </contact>
    <investigator>
      <last_name>Gregg C Newman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center - Aurora</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Beland</last_name>
      <phone>303-418-7639</phone>
      <email>kelly.beland@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jenny R Fox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center - Boulder</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Beland</last_name>
      <phone>303-385-2000</phone>
      <email>kelly.beland@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jenny R Fox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center - Centennial</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Beland</last_name>
      <phone>303-805-7744</phone>
      <email>kelly.beland@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jenny R Fox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center - Colorado Springs</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Beland</last_name>
      <phone>719-577-2555</phone>
      <email>kelly.beland@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jenny R Fox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center - Denver Midtown</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Beland</last_name>
      <phone>303-388-4876</phone>
      <email>kelly.beland@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jenny R Fox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center - Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Beland</last_name>
      <phone>303-321-0302</phone>
      <email>kelly.beland@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jenny R Fox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center - Swedish Medical Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Beland</last_name>
      <phone>303-740-8200</phone>
      <email>kelly.beland@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jenny R Fox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers - Lakewood</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Beland</last_name>
      <phone>303-430-2700</phone>
      <email>kelly.beland@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jenny R Fox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center - Littleton</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Beland</last_name>
      <phone>303-730-4700</phone>
      <email>kelly.beland@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jenny R Fox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center - Lone Tree</name>
      <address>
        <city>Lone Tree</city>
        <state>Colorado</state>
        <zip>80124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Beland</last_name>
      <phone>303-925-0700</phone>
      <email>kelly.beland@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jenny R Fox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center - Longmont</name>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <zip>80501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Beland</last_name>
      <phone>303-684-1900</phone>
      <email>kelly.beland@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jenny R Fox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center - Pueblo</name>
      <address>
        <city>Pueblo</city>
        <state>Colorado</state>
        <zip>81008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Beland</last_name>
      <phone>719-296-6000</phone>
      <email>kelly.beland@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jenny R Fox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center - Thornton</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <zip>80260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Beland</last_name>
      <phone>303-386-7622</phone>
      <email>kelly.beland@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jenny R Fox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Centers of Brevard, Inc.</name>
      <address>
        <city>Palm Bay</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Schmitt</last_name>
      <email>deborah.schmitt@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Venkat Pavan R Kancharla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Specialists - Arlington Heights</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Glidden</last_name>
      <phone>847-259-4482</phone>
      <email>andrea.glidden@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Laura Palmisano</last_name>
      <email>laura.palmisano@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kristen B Wendell, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Specialists - Niles</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisbeth B Lynn</last_name>
      <phone>847-827-9060</phone>
      <email>lisbeth.lynn@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Sara Majcher</last_name>
      <email>sara.majcher@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kristen B Wendell, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology, P.A. - Bethesda</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Almand</last_name>
      <phone>301-424-6231</phone>
      <email>missy.almand@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Carolyn Hendricks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology, P.A. - Brandywine</name>
      <address>
        <city>Brandywine</city>
        <state>Maryland</state>
        <zip>20613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Almand</last_name>
      <phone>301-812-3900</phone>
      <email>missy.almand@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Carolyn Hendricks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology, P.A. - Clinton</name>
      <address>
        <city>Clinton</city>
        <state>Maryland</state>
        <zip>20735</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Almand</last_name>
      <phone>301-868-7911</phone>
      <email>missy.almand@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Carolyn Hendricks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology, P.A. - Columbia</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Almand</last_name>
      <phone>410-964-2212</phone>
      <email>missy.almand@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Carolyn Hendricks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology, P.A. - Frederick</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Almand</last_name>
      <phone>301-695-6777</phone>
      <email>missy.almand@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Carolyn Hendricks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology, P.A. - Lanham</name>
      <address>
        <city>Lanham</city>
        <state>Maryland</state>
        <zip>20706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Almand</last_name>
      <phone>301-474-0427</phone>
      <email>missy.almand@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Carolyn Hendricks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology, P.A. - Rockville - Aquilino Cancer Center</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Almand</last_name>
      <phone>301-424-6231</phone>
      <email>missy.almand@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Carolyn Hendricks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology, P.A. - Silver Spring - White Oak Cancer Center</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Almand</last_name>
      <phone>301-933-3216</phone>
      <email>missy.almand@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Carolyn Hendricks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, P.C. - Albany Cancer Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Zuchelkowski</last_name>
      <phone>518-489-2607</phone>
      <email>amy.zuchelkowski@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Karen L Tedesco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, P.C. - Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Zuchelkowski</last_name>
      <phone>518-262-6696</phone>
      <email>amy.zuchelkowski@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Karen L Tedesco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Broome Oncology, LLC - Binghamton</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Driguneswar Pinnamaneni</last_name>
      <phone>607-763-8065</phone>
      <email>epinnamaneni@broomeoncology.com</email>
    </contact>
    <investigator>
      <last_name>Ronald P Harris, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, P.C. - Clifton Park Cancer Center</name>
      <address>
        <city>Clifton Park</city>
        <state>New York</state>
        <zip>12065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Zuchelkowski</last_name>
      <phone>518-831-4434</phone>
      <email>amy.zuchelkowski@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Karen L Tedesco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Broome Oncology, LLC - Johnson City</name>
      <address>
        <city>Johnson City</city>
        <state>New York</state>
        <zip>13790</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Driguneswar Pinnamaneni</last_name>
      <phone>607-763-6850</phone>
      <email>epinnamaneni@broomeoncology.com</email>
    </contact>
    <investigator>
      <last_name>Ronald P Harris, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Allen</name>
      <address>
        <city>Allen</city>
        <state>Texas</state>
        <zip>75013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shalane Durbin</last_name>
      <phone>469-467-4392</phone>
      <email>shalane.durbin@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Monte F Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Arlington North</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Arant-Daigle</last_name>
      <phone>817-664-9600</phone>
      <email>deborah.arant-daigle@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>John W Adams, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Arlington South</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Arant-Daigle</last_name>
      <phone>817-467-6092</phone>
      <email>deborah.arant-daigle@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>John W Adams, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Beaumont</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alana Brown</last_name>
      <phone>409-813-1686</phone>
      <email>alana.brown@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Scott A McKenney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Beaumont Mamie McFaddin Ward Cancer Center</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alana Brown</last_name>
      <phone>409-899-7180</phone>
      <email>alana.brown@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Scott A McKenney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Carrollton</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Tyree</last_name>
      <phone>972-537-4143</phone>
      <email>kristen.tyree@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Nieves Contreras Alcantara</last_name>
      <email>nieves.contrerasalcantara@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Vibha T Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Methodist Dallas Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lakshmi P Kannan, MD</last_name>
      <phone>214-943-9911</phone>
      <email>lakshmi.kannan@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Ashwani K Agarwal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Medical City Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Brecher</last_name>
      <phone>972-566-4291</phone>
      <email>jason.brecher@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jay G Courtright, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Presbyterian Cancer Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Jones</last_name>
      <phone>214-265-2080</phone>
      <email>nancy.jones@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Cathy Barter</last_name>
      <email>catherine.barter@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kristi J McIntyre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Methodist Charlton Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lakshmi P Kannan, MD</last_name>
      <email>lakshmi.kannan@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Ashwani K Agarwal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan B Huntzinger</last_name>
      <phone>214-370-1000</phone>
      <email>jonathan.huntzinger@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Joanne L Blum, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Denton</name>
      <address>
        <city>Denton</city>
        <state>Texas</state>
        <zip>76201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Smith</last_name>
      <phone>940-382-1022</phone>
      <email>nancy.smith2@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Charles V Kurkul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - El Paso Cancer Treatment Center Grandview</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanya Jauch-Worley</last_name>
      <phone>915-544-6750</phone>
      <email>tanya.jauchworley@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Linley</last_name>
      <email>michelle.linley@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ines J Sanchez-Rivera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - El Paso Cancer Treatment Center Gateway</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79915</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanya Jauch-Worley</last_name>
      <phone>915-599-1313</phone>
      <email>tanya.jauchworley@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Linley</last_name>
      <email>michelle.linley@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ines J Sanchez-Rivera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - El Paso Cancer Treatment Center Joe Battle</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79938</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanya Jauch-Worley</last_name>
      <phone>915-849-2700</phone>
      <email>tanya.jauchworley@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Linley</last_name>
      <email>michelle.linley@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ines J Sanchez-Rivera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Flower Mound</name>
      <address>
        <city>Flower Mound</city>
        <state>Texas</state>
        <zip>75028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Tyree</last_name>
      <phone>972-537-4100</phone>
      <email>kristen.tyree@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Nieves Contreras Alcantara</last_name>
      <email>nieves.contrerasalcantara@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Vibha T Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Harlingen</name>
      <address>
        <city>Harlingen</city>
        <state>Texas</state>
        <zip>78550</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Myers</last_name>
      <phone>956-425-8845</phone>
      <email>monica.myers@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Norma Magallan</last_name>
      <email>norma.magallan@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Alvaro Restrepo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Memorial City</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Fru</last_name>
      <phone>713-467-1722</phone>
      <email>nina.fru@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Michelina Cairo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Willowbrook</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77070</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerrie M Shojaie</last_name>
      <phone>281-894-8822</phone>
      <email>kerrie.shojaie@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Henna M Malik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Longview Cancer Center</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Poe</last_name>
      <phone>903-757-2122</phone>
      <email>karen.poe@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Sasha Strain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - McAllen</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Myers</last_name>
      <phone>956-687-5150</phone>
      <email>monica.myers@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Norma Magallan</last_name>
      <email>norma.magallan@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Alvaro Restrepo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - McKinney</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75071</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shalane Durbin</last_name>
      <phone>972-542-8609</phone>
      <email>shalane.durbin@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Monte F Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - New Braunfels</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debora E Lind</last_name>
      <phone>830-643-1762</phone>
      <email>debora.lind@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Emmalind Aponte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Paris</name>
      <address>
        <city>Paris</city>
        <state>Texas</state>
        <zip>75460</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue J Crumpler</last_name>
      <phone>903-785-0031</phone>
      <email>sue.crumpler@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Sucharu Prakash, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Plano West</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yue Feng</last_name>
      <phone>972-596-7801</phone>
      <email>yue.feng@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Philip A Kovoor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - San Antonio Downtown</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debora E Lind</last_name>
      <phone>210-224-6531</phone>
      <email>debora.lind@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Emmalind Aponte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - San Antonio Northeast</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debora E Lind</last_name>
      <phone>210-656-7177</phone>
      <email>debora.lind@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Emmalind Aponte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debora E Lind</last_name>
      <phone>210-595-5300</phone>
      <email>debora.lind@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Emmalind Aponte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - San Antonio Stone Oak</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debora E Lind</last_name>
      <phone>210-545-6972</phone>
      <email>debora.lind@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Emmalind Aponte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Sherman</name>
      <address>
        <city>Sherman</city>
        <state>Texas</state>
        <zip>75090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jayne Mettetal</last_name>
      <phone>903-892-9455</phone>
      <email>jayne.mettetal@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Tammy E Roque, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Sugar Land</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Howell</last_name>
      <phone>281-277-5200</phone>
      <email>melissa.howell@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Caesar K Tin-U, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - The Woodlands</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Lopez</last_name>
      <phone>281-296-0365</phone>
      <email>ruth.lopez1@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Veta Clayton</last_name>
      <email>veta.clayton@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Paula D Ryan, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Poe</last_name>
      <phone>903-579-9800</phone>
      <email>karen.poe@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Sasha Strain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Horizon Circle</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Fonseca</last_name>
      <phone>254-399-0741</phone>
      <email>laura.fonseca@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Carlos A Encarnacion, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Waco</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Fonseca</last_name>
      <phone>254-399-0741</phone>
      <email>laura.fonseca@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Carlos A Encarnacion, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Deke Slayton Cancer Center</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara Gray</last_name>
      <phone>281-332-7505</phone>
      <email>tara.gray@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Dhatri Kodali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Weslaco</name>
      <address>
        <city>Weslaco</city>
        <state>Texas</state>
        <zip>78596</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nereida Salinas</last_name>
      <phone>956-969-0021</phone>
      <email>nereida.salinas@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Aide Borrego</last_name>
      <email>aide.borrego@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Alvaro Restrepo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC - Alexandria</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcy Sullivan</last_name>
      <phone>703-832-5322</phone>
      <email>marcy.sullivan@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Mitul Gandhi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC - Arlington</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcy Sullivan</last_name>
      <phone>703-528-7303</phone>
      <email>marcy.sullivan@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Mitul Gandhi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC - Fairfax</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcy Sullivan</last_name>
      <phone>703-280-5390</phone>
      <email>marcy.sullivan@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Mitul Gandhi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC - Gainesville</name>
      <address>
        <city>Gainesville</city>
        <state>Virginia</state>
        <zip>20155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcy Sullivan</last_name>
      <phone>571-222-2200</phone>
      <email>marcy.sullivan@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Mitul Gandhi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC - Loudoun</name>
      <address>
        <city>Leesburg</city>
        <state>Virginia</state>
        <zip>20176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcy Sullivan</last_name>
      <phone>703-554-6800</phone>
      <email>marcy.sullivan@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Mitul Gandhi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shenandoah Oncology, P.C.</name>
      <address>
        <city>Winchester</city>
        <state>Virginia</state>
        <zip>22601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William A Houck III, MD</last_name>
      <phone>540-662-1108</phone>
      <email>william.houck@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>William A Houck III, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Noordhoek I, Treuner K, Putter H, Zhang Y, Wong J, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, van de Velde CJH, Schnabel CA, Liefers GJ. Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR(+) Early-stage Breast Cancer for 10 Years of Endocrine Therapy. Clin Cancer Res. 2021 Jan 1;27(1):311-319. doi: 10.1158/1078-0432.CCR-20-2737. Epub 2020 Oct 27.</citation>
    <PMID>33109739</PMID>
  </reference>
  <reference>
    <citation>Bartlett JMS, Sgroi DC, Treuner K, Zhang Y, Ahmed I, Piper T, Salunga R, Brachtel EF, Pirrie SJ, Schnabel CA, Rea DW. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial. Ann Oncol. 2019 Nov 1;30(11):1776-1783. doi: 10.1093/annonc/mdz289.</citation>
    <PMID>31504126</PMID>
  </reference>
  <reference>
    <citation>Zhang Y, Schnabel CA, Schroeder BE, Jerevall PL, Jankowitz RC, Fornander T, Stl O, Brufsky AM, Sgroi D, Erlander MG. Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence. Clin Cancer Res. 2013 Aug 1;19(15):4196-205. doi: 10.1158/1078-0432.CCR-13-0804. Epub 2013 Jun 11.</citation>
    <PMID>23757354</PMID>
  </reference>
  <reference>
    <citation>Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, Erlander MG, Dunbier A, Sidhu K, Lopez-Knowles E, Goss PE, Dowsett M. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol. 2013 Oct;14(11):1067-1076. doi: 10.1016/S1470-2045(13)70387-5. Epub 2013 Sep 12. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.</citation>
    <PMID>24035531</PMID>
  </reference>
  <reference>
    <citation>Sgroi DC, Carney E, Zarrella E, Steffel L, Binns SN, Finkelstein DM, Szymonifka J, Bhan AK, Shepherd LE, Zhang Y, Schnabel CA, Erlander MG, Ingle JN, Porter P, Muss HB, Pritchard KI, Tu D, Rimm DL, Goss PE. Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J Natl Cancer Inst. 2013 Jul 17;105(14):1036-42. doi: 10.1093/jnci/djt146. Epub 2013 Jun 28.</citation>
    <PMID>23812955</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 26, 2021</study_first_submitted>
  <study_first_submitted_qc>May 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2021</study_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Neoplasm</keyword>
  <keyword>Invasive Breast Carcinoma</keyword>
  <keyword>Early Stage (I, II or III) Breast Cancer</keyword>
  <keyword>Hormone Receptor positive (HR+) Breast Cancer</keyword>
  <keyword>Extended Endocrine Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

